Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) Director Sells $855,480.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) Director Raymond Dwek sold 3,000 shares of United Therapeutics stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $285.16, for a total transaction of $855,480.00. Following the sale, the director now directly owns 1,750 shares in the company, valued at $499,030. The trade was a 63.16 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Raymond Dwek also recently made the following trade(s):

• On Monday, April 7th, Raymond Dwek sold 4,000 shares of United Therapeutics stock. The stock was sold at an average price of $284.55, for a total transaction of $1,138,200.00.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $284.73 on Friday. United Therapeutics Co. has a 1 year low of $233.28 and a 1 year high of $417.82. The company has a market cap of $12.79 billion, a P/E ratio of 12.50, a PEG ratio of 0.97 and a beta of 0.63. The stock’s fifty day moving average price is $317.98 and its 200-day moving average price is $349.16.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. The business had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period in the previous year, the company posted $4.36 EPS. On average, sell-side analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Institutional Trading of United Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of UTHR. Newbridge Financial Services Group Inc. purchased a new stake in United Therapeutics in the 4th quarter worth $25,000. Dunhill Financial LLC boosted its stake in United Therapeutics by 100.0% in the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 50 shares during the period. Sound Income Strategies LLC purchased a new stake in United Therapeutics during the 1st quarter valued at approximately $49,000. State of Wyoming bought a new stake in shares of United Therapeutics during the fourth quarter valued at approximately $62,000. Finally, Millstone Evans Group LLC purchased a new position in shares of United Therapeutics in the fourth quarter worth $67,000. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. UBS Group raised their target price on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $425.00 target price on shares of United Therapeutics in a research report on Thursday, February 27th. One analyst has rated the stock with a sell rating, two have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $388.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.